Research programme: T-cell modulators - Medigene AGAlternative Names: Adoptive T-cell therapy; T-cell antibodies - TABs; TCR modified T-cells; TCR-specific antibodies-Medigene Immunotherapies
Latest Information Update: 21 Nov 2016
At a glance
- Originator Trianta Immunotherapies
- Developer MediGene AG
- Class Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; T-cell leukaemia